Level A· Stronger Clinical EvidenceSystematic Review

Stem cell-based interventions for the treatment of stroke in newborn infants.

Bruschettini M., Badura A., Romantsik O.

Systematic Review on Stroke Research, published in Cochrane Database Syst Rev (2023) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type: Systematic Review
Journal: Cochrane Database Syst Rev (2023)
Country: England
Reported sample size: —
PMID: 37994736
DOI: 10.1002/14651858.CD015582.pub2
NCT: NCT03356821

Abstract (original English)

Perinatal stroke refers to a diverse but specific group of cerebrovascular diseases that occur between 20 weeks of fetal life and 28 days of postnatal life. Acute treatment options for perinatal stroke are limited supportive care, such as controlling hypoglycemia and seizures. Stem cell-based therapies offer a potential therapeutic approach to repair, restore, or regenerate injured brain tissue. Preclinical findings have culminated in ongoing human neonatal studies. To evaluate the benefits and harms of stem cell-based interventions for the treatment of stroke in newborn infants compared to control (placebo or no treatment) or stem-cell based interventions of a different type or source. We searched CENTRAL, PubMed, Embase, and three trials registries in February 2023. We planned to search the reference lists of included studies and relevant systematic reviews for studies not identified by the database searches. We attempted to include randomized controlled trials, quasi-randomized controlled trials, and cluster trials that evaluated any of the following comparisons. • Stem cell-based interventions (any type) versus control (placebo or no treatment) • Mesenchymal stem/stromal cells (MSCs) of a specifictype (e.g. number of doses or passages) or source (e.g. autologous/allogeneic or bone marrow/cord) versus MSCs of another type or source • Stem cell-based interventions (other than

What this study does not prove

• This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence

Infant, NewbornPregnancyFemaleInfantHumansInfant MortalityStem Cell TransplantationStrokeSeizures

Systemic / IV Stroke Research

View on PubMed DOI

Stem cell-based interventions for the treatment of stroke in newborn infants.

Abstract (original English)

What this study does not prove

Evidence level

Related research

Plasma Biomarkers Associated With Heart Failure Hospitalization Among Patients With Atrial Fibrillation and Subtypes of Heart Failure.

The inconclusive superiority debate of allogeneic versus autologous MSCs in treating patients with HFrEF: a systematic review and meta-analysis of RCTs.

Safety and Efficacy of Bone Marrow and Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Ischemic Stroke: A Systematic Review.

Stem cell-derived exosomes for ischemic stroke: a conventional and network meta-analysis based on animal models.

Arterial Embolism After Facial Fat Grafting: A Systematic Literature Review.

Paracrine Factors Released by Stem Cells of Mesenchymal Origin and their Effects in Cardiovascular Disease: A Systematic Review of Pre-clinical Studies.